pembrolizumab
merck
['keynote-826', 'pembro']
#asco2023 final os of keynote-826 confirming survival advantage of pembrolizumab in persistent,recurrent, metastatic cervical cancer. a one year improvement in median os and the tail of the curve is provocative! 
Gyn Oncologist with passion for excellent patient care, clinical trials and drug development. Associate professor @UCSD_OBGYN, views = own